том 117 издание 14 страницы 3869-3880

KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia

Тип публикацииJournal Article
Дата публикации2011-04-07
SCImago Q1
Tоп 10% SCImago
WOS Q1
БС1
SJR5.912
CiteScore22.8
Impact factor23.9
ISSN00064971, 15280020
Biochemistry
Cell Biology
Immunology
Hematology
Краткое описание

The histone H3 lysine 36 dimethyl–specific demethylase KDM2b/JHDM1b, which is highly expressed in various human leukemias, was previously found to be important in regulating cell proliferation and cellular senescence. However, its functions in leukemia development and maintenance are unclear. Here, we demonstrate that ectopic expression of Kdm2b/Jhdm1b is sufficient to transform hematopoietic progenitors. Conversely, depletion of Kdm2b/Jhdm1b in hematopoietic progenitors significantly impairs Hoxa9/Meis1-induced leukemic transformation. In leukemic stem cells, knockdown of Kdm2b/Jhdm1b impairs their self-renewing capability in vitro and in vivo. The functions of Kdm2b/Jhdm1b are mediated by its silencing of p15Ink4b expression through active demethylation of histone H3 lysine 36 dimethyl. Thus, our study suggests that Kdm2b/Jhdm1b functions as an oncogene and plays a critical role in leukemia development and maintenance.

Для доступа к списку цитирований публикации необходимо авторизоваться.

Топ-30

Журналы

1
2
3
4
5
6
bioRxiv
6 публикаций, 3.39%
Epigenomics
4 публикации, 2.26%
Signal Transduction and Targeted Therapy
3 публикации, 1.69%
Frontiers in Oncology
3 публикации, 1.69%
Oncogene
3 публикации, 1.69%
Cell Death and Disease
3 публикации, 1.69%
Experimental Cell Research
3 публикации, 1.69%
Experimental Hematology
3 публикации, 1.69%
Journal of Medicinal Chemistry
3 публикации, 1.69%
Journal of Clinical Investigation
2 публикации, 1.13%
Current Medicinal Chemistry
2 публикации, 1.13%
Oncotarget
2 публикации, 1.13%
Cells
2 публикации, 1.13%
Frontiers in Genetics
2 публикации, 1.13%
Frontiers in Molecular Medicine
2 публикации, 1.13%
Experimental and Molecular Medicine
2 публикации, 1.13%
Nature
2 публикации, 1.13%
Leukemia
2 публикации, 1.13%
PLoS ONE
2 публикации, 1.13%
Cancer Cell
2 публикации, 1.13%
Trends in Immunology
2 публикации, 1.13%
Trends in Cell Biology
2 публикации, 1.13%
International Journal of Cancer
2 публикации, 1.13%
Cancer Drug Discovery and Development
2 публикации, 1.13%
Journal of Virology
2 публикации, 1.13%
Blood
2 публикации, 1.13%
Cancers
2 публикации, 1.13%
Environmental Health Perspectives
1 публикация, 0.56%
Biochemical Journal
1 публикация, 0.56%
1
2
3
4
5
6

Издатели

5
10
15
20
25
30
35
40
45
Elsevier
44 публикации, 24.86%
Springer Nature
36 публикаций, 20.34%
Wiley
16 публикаций, 9.04%
MDPI
10 публикаций, 5.65%
Taylor & Francis
9 публикаций, 5.08%
Frontiers Media S.A.
9 публикаций, 5.08%
American Chemical Society (ACS)
6 публикаций, 3.39%
openRxiv
6 публикаций, 3.39%
Public Library of Science (PLoS)
3 публикации, 1.69%
American Society for Microbiology
3 публикации, 1.69%
American Association for the Advancement of Science (AAAS)
3 публикации, 1.69%
American Society for Clinical Investigation
2 публикации, 1.13%
Bentham Science Publishers Ltd.
2 публикации, 1.13%
Impact Journals
2 публикации, 1.13%
Portland Press
2 публикации, 1.13%
Ovid Technologies (Wolters Kluwer Health)
2 публикации, 1.13%
Oxford University Press
2 публикации, 1.13%
American Association for Cancer Research (AACR)
2 публикации, 1.13%
American Society of Hematology
2 публикации, 1.13%
Environmental Health Perspectives
1 публикация, 0.56%
Spandidos Publications
1 публикация, 0.56%
SAGE
1 публикация, 0.56%
Higher Education Press
1 публикация, 0.56%
American Society for Biochemistry and Molecular Biology
1 публикация, 0.56%
Federation of American Societies for Experimental Biology (FASEB)
1 публикация, 0.56%
Japan Society for Cell Biology
1 публикация, 0.56%
De Gruyter Brill
1 публикация, 0.56%
Ferrata Storti Foundation
1 публикация, 0.56%
eLife Sciences Publications
1 публикация, 0.56%
5
10
15
20
25
30
35
40
45
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
 Войти с ORCID
Метрики
177
Поделиться
Цитировать
ГОСТ |
Цитировать
He J. et al. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia // Blood. 2011. Vol. 117. No. 14. pp. 3869-3880.
ГОСТ со всеми авторами (до 50) Скопировать
He J., Nguyen A. T., Zhang Y. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia // Blood. 2011. Vol. 117. No. 14. pp. 3869-3880.
RIS |
Цитировать
TY - JOUR
DO - 10.1182/blood-2010-10-312736
UR - https://doi.org/10.1182/blood-2010-10-312736
TI - KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia
T2 - Blood
AU - He, Jin
AU - Nguyen, Anh Tram
AU - Zhang, Yi
PY - 2011
DA - 2011/04/07
PB - American Society of Hematology
SP - 3869-3880
IS - 14
VL - 117
PMID - 21310926
SN - 0006-4971
SN - 1528-0020
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2011_He,
author = {Jin He and Anh Tram Nguyen and Yi Zhang},
title = {KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia},
journal = {Blood},
year = {2011},
volume = {117},
publisher = {American Society of Hematology},
month = {apr},
url = {https://doi.org/10.1182/blood-2010-10-312736},
number = {14},
pages = {3869--3880},
doi = {10.1182/blood-2010-10-312736}
}
MLA
Цитировать
He, Jin, et al. “KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.” Blood, vol. 117, no. 14, Apr. 2011, pp. 3869-3880. https://doi.org/10.1182/blood-2010-10-312736.
Ошибка в публикации?